AI Article Synopsis

  • The study focused on severe acute necrotizing encephalopathy (ANE) in children infected with SARS-CoV-2, aiming to identify early signs of ANE and the effectiveness of tocilizumab as a treatment option.
  • Out of 19 cases analyzed, 42% resulted in death, while 47% showed improvement with lingering neurological issues; common symptoms included high fever, convulsions, and altered consciousness.
  • The combination of classical treatment with tocilizumab significantly lowered mortality rates in comparison to classical treatment alone, suggesting tocilizumab may be beneficial for ANE in this context.

Article Abstract

Background And Objective: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes acute necrotizing encephalopathy (ANE), which has a high mortality rate and severe sequelae. This study aimed to identify ANE early and evaluate the usefulness of tocilizumab in ANE treatment.

Methods: We retrospectively included eight paeefediatric ANE cases infected with SARS-CoV-2 at Xi'an Children's Hospital, China, from December 1, 2022 to May 1, 2023. A literature search was performed using the PUBMED, SPRING, SCOPUS, and EMBASE databases. This study included eleven patients. Clinical characteristics, laboratory test results, imaging features, and treatment options were analysed.

Results: Eight of the 19 cases (42 %) died, one (5 %) recovered, and nine (47 %) improved with residual neurological dysfunction. Eighteen patients presented with fever, with 56 % having ≥40 °C. Twelve patients (63 %) presented with dysfunction consciousness. Eight (42 %) patients experienced frequent convulsions. All eight patients in our hospital had elevated procalcitonin levels (mean: 21.32 ng/mL, range: 0.10-89.40 ng/mL). Alanine aminotransferase levels were elevated (mean: 632.81 U/L, range: 13.00-2251.00 U/L) in six patients. Seven patients showed elevated uric acid levels(mean: 396.50 μmol/L, range: 157.00-660.00 μmol/L). Brain imaging indicated that all the patients had symmetrical injuries to the bilateral thalami, accompanied by symmetrical injuries in the cerebrum, cerebellum, basal ganglia, and brain stem. Compared with the classical treatment (n = 9), the combination with tocilizumab (n = 6) showed a statistically difference in mortality (p = 0.028 < 0.05).

Conclusion: The typical clinical manifestations of ANE in children with SARS-CoV-2 infection are acute onset with high fever, frequent convulsions and rapidly worsening disturbance of consciousness. Tocilizumab treatment could reduces mortality in ANE.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejpn.2024.07.009DOI Listing

Publication Analysis

Top Keywords

acute necrotizing
8
necrotizing encephalopathy
8
infected sars-cov-2
8
patients
8
symmetrical injuries
8
encephalopathy infected
4
sars-cov-2 children
4
children case
4
case series
4
series literature
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!